Florida's Stefel Labs acquires

ABR CORAL GABLES, FL-Stiefel Laboratories Inc., the world's largest independent pharmaceutical company specializing in dermatology, has acquired ABR Invent and ABR Development, developers of the dermal filler Atlean. Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both ABR Invent and ABR Development are legal entities based in France. Atlean dermal filler is currently commercialized in France and Italy and distribution and manufacturing agreements for the product will remain in place throughout Europe. Atlean dermal filler uses a combination of tricalcium phosphate particles suspended in a hyaluronic acid gel. The injectable product is recommended for sculpting and remodelling the face. Hyaluronic acid occurs naturally in skin tissue, transporting and delivering water to the skin, and contributing to its elasticity. As key ingredients in Atlean dermal filler, hyaluronic acid facilitates an immediate and temporary volumizing effect.